NCT05524974

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Clinical Efficacy of Carrelizumab, Apatinib Mesylate, Albumin Paclitaxel Combined With Oxaliplatin and S-1 in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes--A Prospective, Multi-center, Randomized Controlled Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 203 (estimated)
• Sponsor: Fujian Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the clinical efficacy of camrelizumab, apatinib Mesylate and nab-paclitaxel combined with oxplatin and S-1 in the neoadjuvant treatment of locally advanced gastric cancer with different genotypes

Conditions

• Locally Advanced Gastric Cancer

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.
DRUG	Oxaliplatin	Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.
DRUG	S1	S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time
DRUG	Apatinib Mesylate	Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday.
DRUG	Nab paclitaxel	nab-paclitaxel One course will last 21 days. Given twice every 3 weeks at a dose of 260 mg/m2 in day 1 and day 8.

Timeline

• Start date: 2022-09-01
• Primary completion: 2024-09-01
• Completion: 2027-09-01
• First posted: 2022-09-01
• Last updated: 2022-09-01

Locations

1 site across 1 country: China